GLP3 Retatrutide Mechanism of Action – GIP, GLP-1 & Glucagon Triple Agonist
Mechanistic summary for educational purposes. Not dosing guidance or clinical protocol.
Triple-Pathway Design
Retatrutide is engineered to activate three key receptors:
- GIP receptor – may modulate insulin response and metabolic flexibility.
- GLP-1 receptor – associated with appetite regulation, gastric emptying, and glycemic control.
- Glucagon receptor – when precisely dosed, may increase energy expenditure and lipid utilization.
Energy & Weight
The triple-agonist architecture aims to combine appetite reduction with increased caloric expenditure,
potentially explaining the strong weight-loss signals in early trials.
Glycemic Control
GLP-1 and GIP arms support glucose-dependent insulin secretion and improved glycemic markers under supervision.
Precision Required
Glucagon receptor activation requires careful balancing to avoid unwanted hyperglycemia or metabolic stress,
which is why retatrutide remains an investigational molecule.
Why This Matters for GLP3 Weight Loss
As multi-agonists emerge, terms like “GLP3 peptide” circulate online. This page clarifies that
retatrutide is a specific investigational agent, not a generic peptide mix.
For context on data, see the
clinical trials overview.
